Macquarie 11-Mar-14
US testosterone sales fell 15% last week and 11% on a rolling monthly average, the broker notes. While Axiron is quietly gaining market share it is doing so in a market of declining volumes and prices, subject to FDA review, and in the knowledge a new product is likely to enter the race this year.
The broker retains Underperform on Acrux. Target falls to $1.62 from $1.75.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 460415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 40308 | 3 |
View Market Depth
| Last trade - 09.49am 24/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable